Taylor Schreiber
Gründer bei SHATTUCK LABS, INC.
Vermögen: 26 Mio $ am 30.04.2024
Aktive Positionen von Taylor Schreiber
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SHATTUCK LABS, INC. | Direktor/Vorstandsmitglied | 01.01.2016 | - |
| Vorstandsvorsitzender | 01.01.2020 | - | |
| Gründer | 01.01.2016 | - | |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 | 01.01.2020 |
Karriereverlauf von Taylor Schreiber
Ehemalige bekannte Positionen von Taylor Schreiber
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Pelican Therapeutics, Inc.
 Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Direktor/Vorstandsmitglied | 01.01.2011 | 01.01.2017 |
| SCORPIUS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 03.03.2014 | 31.12.2016 |
| SCORPIUS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Taylor Schreiber
| Bucknell University | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SCORPIUS HOLDINGS, INC. | Health Technology |
| SHATTUCK LABS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Pelican Therapeutics, Inc.
Pelican Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Pelican Therapeutics, Inc. operates as an immuno-oncology company. It develops biological agents that represents the next generation of tumor necrosis factor (TNF) based immunotherapy. The company was founded by Jeffrey Wolf and Josiah C. Hornblower on March 6, 2017 and is headquartered in Dallas, TX. | Health Services |
- Börse
- Insiders
- Taylor Schreiber
- Erfahrung
